Table 2.
Primers used in this study
| Primer | Sequence (5′-3′)a |
|---|---|
| HYG-1 | ATATAGGATCCTTGGTTGAATTTAGAACGTGGCACTATTGATC |
| HYG-2 | ATATAAAGCTTTGAAGGCGTTACTAGGTTGCAGTCAATGC |
| AbenACT-1 | CGggATccCATCAGCGGCCGGAGTG |
| AbenACT-2 | CCTCCATGGTGGCTGATAGTAC |
| AbenACUE-1 | CGGTGGCTTCGATGGgcccGATGGAATGTGTAC |
| AbenACUE-2 | CTTCCACCGAGGTaagCTTGCGTTGGTGCTAG |
| AbenACUE-3 | CCATAATGTAAATggatCCTAACATTTTGAACGCGC |
| AbenACUE-4 | CGTGGCTCTAGATAAGCTGAC |
| AbenACUE-9 | CGGTGGCTTCGATGGTCgAcATGGAATGTGTAC |
| NEO-1 | CTCTAGAGGATCCCATCAGC |
| NEO-2 | TATAAAGCTTTTTCAGAAGAACTCGTCAAGAAGGCG |
| AbenKU70-1 | CCGTATCACTGGTCTGGGCCCCGAGCCAGGC |
| AbenKU70-2 | CGCGCACCCAGTTAGAAGCttTGACAGAAGC |
| AbenKU70-3 | CGAATTATCAAGCCTCTAACTCGGatccTAATATAGCTC |
| AbenKU70-4 | GGACAACGCGGGCcGCGGCGGGCAGCGTTACCC |
a
The lowercase letters represent nucleotide exchanges introduced to create the underlined restriction sites.